ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Digital oral presentations: DOP Session 3 - Improving care of IBD (2020)

DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months

DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine

DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study

DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)

DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe

DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial

DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort

DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease

DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure